Tevogen Inc(TVGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.83 | Insider Own | - | Shs Outstand | 4.3M | Perf Week | -3.11% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -7.56% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | - | Inst Own | 1.64% | Short Float | - | Perf Quarter | -7.14% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | -27.11% | Short Ratio | 6.28 | Perf Half Y | -2.8% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -480.45% | Short Interest | 0.06M | Perf YTD | -62.31% |
| Book/sh | -4.16 | P/C | 37.62 | EPS past 3/5Y | - -305.12% | ROE | - | 52W High | -80.8% ($32.50) | Perf Year | -79.37% |
| Cash/sh | 0.17 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 71.6% ($3.64) | Perf 3Y | -98.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 36.06% | Gross Margin | - | Volatility(W/M) | 10.06% 8.48% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.33 | EPS Q/Q | 0.36% | Profit Margin | - | RSI (14) | 41.69 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.33 | Sales Q/Q | - | SMA20 | -6.66% ($6.69) | Beta | 0.2 | Target Price | $100 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -10.31% ($6.96) | Rel Volume | 2.43 | Prev Close | $6.28 |
| Employees | 18 | LT Debt/Eq | - | EPS/Sales Surpr. | 50.66% - | SMA200 | -25.09% ($8.33) | Avg Volume(3M) | 0.01M | Price | $6.24 |
| IPO | 2022/1/5 | Option/Short | No/Yes | Trades | 979 | Volume | 21,467 | Change | -0.64% |
🧫 Tevogen Bio (Tevogen Biosciences) is a clinical-stage biotech developing off-the-shelf precision T-cell therapies using its 'ExacTcell' platform to target viruses, cancer, and autoimmune diseases. Its lead candidate, TVGN 489, is a SARS-CoV-2-specific CD8+ T-cell therapy.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded more than usual. That is 243% of its average volume.
TVGN has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -98.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #435 of 594 in the industry
Based on market cap of $41M.
FAQ
What kind of company is TVGN?
TVGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TVGN?
The market cap of TVGN is approximately $41M, ranking 4,960 within its sector.
What is the 52-week high and low for TVGN?
TVGN has recorded a 52-week high of $32.50 and a low of $3.64.
